Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

June 13, 2020

Primary Completion Date

November 16, 2020

Study Completion Date

November 16, 2020

Conditions
COVID-19
Interventions
DRUG

Acalabrutinib

Acalabrutinib administered orally

Trial Locations (31)

10029

Research Site, New York

10467

Research Site, The Bronx

12208

Research Site, Albany

14263

Research Site, Buffalo

19140

Research Site, Philadelphia

20010

Research Site, Washington D.C.

20889

Research Site, Bethesda

20910

Research Site, Silver Spring

21287

Research Site, Baltimore

21401

Research Site, Annapolis

23298

Research Site, Richmond

32207

Research Site, Jacksonville

32209

Research Site, Jacksonville

33308

Research Site, Fort Lauderdale

33470

Research Site, Loxahatchee Groves

36207

Research Site, Anniston

36604

Research Site, Mobile

38120

Research Site, Nashville

40207

Research Site, Louisville

46804

Research Site, Fort Wayne

75701

Research Site, Tyler

77030

Research Site, Houston

77090

Research Site, Houston

91206

Research Site, Glendale

92029

Research Site, Escondido

92663

Research Site, Newport Beach

92835

Research Site, Fullerton

98055

Research Site, Renton

06519

Research Site, New Haven

20892-1374

Research Site, Bethesda

07601

Research Site, Hackensack

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Acerta Pharma BV

INDUSTRY

lead

AstraZeneca

INDUSTRY